Neil M. Iyengar, Joyce O’Shaughnessy, Heather Moore, Erika Hamilton, Komal Jhaveri, X. Cynthia, Karen L. Tedesco, Monali Vasekar, Sarah Donahue, Hope S. Rugo
Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.